These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 10992450)
21. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults. Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907 [TBL] [Abstract][Full Text] [Related]
22. Global diversity of the gene encoding the Pfs25 protein-a Plasmodium falciparum transmission-blocking vaccine candidate. Sookpongthai P; Utayopas K; Sitthiyotha T; Pengsakul T; Kaewthamasorn M; Wangkanont K; Harnyuttanakorn P; Chunsrivirot S; Pattaradilokrat S Parasit Vectors; 2021 Nov; 14(1):571. PubMed ID: 34749796 [TBL] [Abstract][Full Text] [Related]
23. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Zou L; Miles AP; Wang J; Stowers AW Vaccine; 2003 Apr; 21(15):1650-7. PubMed ID: 12639486 [TBL] [Abstract][Full Text] [Related]
24. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016 [TBL] [Abstract][Full Text] [Related]
25. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140 [TBL] [Abstract][Full Text] [Related]
32. Fusion to Tetrahymena thermophila granule lattice protein 1 confers solubility to sexual stage malaria antigens in Escherichia coli. Agrawal A; Bisharyan Y; Papoyan A; Bednenko J; Cardarelli J; Yao M; Clark T; Berkmen M; Ke N; Colussi P Protein Expr Purif; 2019 Jan; 153():7-17. PubMed ID: 30081196 [TBL] [Abstract][Full Text] [Related]
33. Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial. de Graaf H; Payne RO; Taylor I; Miura K; Long CA; Elias SC; Zaric M; Minassian AM; Silk SE; Li L; Poulton ID; Baker M; Draper SJ; Gbesemete D; Brendish NJ; Martins F; Marini A; Mekhaiel D; Edwards NJ; Roberts R; Vekemans J; Moyle S; Faust SN; Berrie E; Lawrie AM; Hill F; Hill AVS; Biswas S Front Immunol; 2021; 12():694759. PubMed ID: 34335606 [TBL] [Abstract][Full Text] [Related]
34. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles. Lalitha PV; Biswas S; Pillai CR; Saxena RK Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786 [TBL] [Abstract][Full Text] [Related]
35. Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes. Miura K; Jongert E; Deng B; Zhou L; Lusingu JP; Drakeley CJ; Fay MP; Long CA; Vekemans J Malar J; 2014 Jul; 13():263. PubMed ID: 25007730 [TBL] [Abstract][Full Text] [Related]
36. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858 [TBL] [Abstract][Full Text] [Related]
37. Efficacy model for mosquito stage transmission blocking vaccines for malaria. Saul A Parasitology; 2008 Nov; 135(13):1497-506. PubMed ID: 18257944 [TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults. Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674 [TBL] [Abstract][Full Text] [Related]
40. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. Wu Y; Ellis RD; Shaffer D; Fontes E; Malkin EM; Mahanty S; Fay MP; Narum D; Rausch K; Miles AP; Aebig J; Orcutt A; Muratova O; Song G; Lambert L; Zhu D; Miura K; Long C; Saul A; Miller LH; Durbin AP PLoS One; 2008 Jul; 3(7):e2636. PubMed ID: 18612426 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]